Aliskiren fumarate  (Synonyms: CGP 60536 fumarate; CGP60536B fumarate; SPP 100 fumarate)

Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC₅₀ of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia^[1][2][3].

IC50: 1.5 nM (renin)^[1]

Aliskiren fumarate (< 10 mg/kg, Orally, daily) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets^[2].
Aliskiren fumarate (10 mg/kg, Intragastrically, once) significantly alleviates multiple cachexia‑associated symptoms in BALB/c mice bearing C26 mouse colon carcinoma cells, including BW loss, tumor burden, muscle wasting, muscular dysfunction, and shortened survival^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

667.83

C₃₄H₅₇N₃O₁₀

1196835-68-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754–758  [Content Brief]

  [2]. Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705.  [Content Brief]

  [3]. Wang C, et al. Aliskiren targets multiple systems to alleviate cancer cachexia. Oncol Rep. 2016 Nov;36(5):3014-3022.  [Content Brief]